Objective Our overall project is to develop and prepare to commercialise a rapid, cost-effective platform for near-patient diagnosis using multiplex immunoassays. Development of a cost-effective system for diagnosis by multiplex biomarker analysis at the point-of-care is essential to enable the delivery of modern, stream-lined healthcare systems in the EU and globally that rapidly and accurately assesses patient needs at the earliest opportunity.Immunoassays are a mainstay of clinical diagnoses. ELISA tests provide sensitive, accurate and quantitative diagnostic data for a large number of disease biomarkers. The technology has not changed for decades and requires central laboratory facilities. Each test measures only one biomarker and takes up to 2 hours to perform.NALIA Systems’ technology provides multiplexed ELISA tests in which panels of 10-15 biomarkers can be tested in parallel, whilst retaining the sensitivity, accuracy and quantification benefits of standard ELISA tests. The first NALIA Arrays are now being made available for use in laboratories.Standard ELISA technology cannot be adapted for use at point-of-care due to the time to result and the complex liquid handling needed. In contrast, the inherent characteristics of NALIA’s array technology mean that it can be incorporated into disposable cartridges and dramatically reduce the time to result.This project will develop a bench-top device and disposable cartridge system for biomarker arrays for diagnosis at the point of care. Initial arrays will be for autoimmune disorders, allergy and infectious diseases, followed by oncology and other diseases.In Phase 1 we intend to confirm the feasibility of achieving a result in <20min; to prepare a product development plan that will lead to a manufacturable device and series of cartridges; to complete a business plan covering all aspects of the commercial opportunity, pricing, market size, competition and route to market; and submit an application for Phase 2 funding. Fields of science natural sciencesphysical sciencesclassical mechanicsfluid mechanicsmicrofluidicsmedical and health scienceshealth sciencesinfectious diseasesmedical and health sciencesbasic medicineimmunologyautoimmune diseasesmedical and health sciencesclinical medicineoncologymedical and health sciencesclinical medicineallergology Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Topic(s) PHC-12-2015-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices Call for proposal H2020-SMEInst-2014-2015 See other projects for this call Sub call H2020-SMEINST-1-2015 Funding Scheme SME-1 - SME instrument phase 1 Coordinator NALIA SYSTEMS LIMITED Net EU contribution € 50 000,00 Address C/O DUBOFF & CO, KINGSBURY HOUSE, 468 CHURCH LANE NW9 8UA LONDON United Kingdom See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region London Outer London — West and North West Brent Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 71 429,00
